ANTIHYPERTENSIVE EFFICACY OF OLMESARTAN MEDOXOMIL, A NEW ANGIOTENSIN II RECEPTOR ANTAGONIST, AS ASSESSED BY AMBULATORY BLOOD PRESSURE MEASUREMENTS
Olmesartan medoxomil is a new angiotensin II receptor blocker. In this randomized, double-blind, placebo-controlled study, the efficacy and safety of olmesartan medoxomil was assessed in 334 patients with moderate to severe essential hypertension. Patients were randomized to receive placebo; 5, 20,...
Saved in:
| Main Authors: | J. M. Neutel, W. J. Elliott, J. L. Izzo, C. L. Chen, H. N. Masonson |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«FIRMA «SILICEA» LLC
2011-04-01
|
| Series: | Российский кардиологический журнал |
| Subjects: | |
| Online Access: | https://russjcardiol.elpub.ru/jour/article/view/1155 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
EVALUATION OF ANTIHYPERTENSIVE THERAPY WITH THE COMBINATION OF OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE
by: Steven G. Chrysant, et al.
Published: (2011-06-01) -
EFFECT OF ANGIOTENSIN RECEPTOR BLOCKADE ON ENDOTHELIAL FUNCTION: FOCUS ON OLMESARTAN MEDOXOMIL
by: C. Ferrario
Published: (2010-12-01) -
Optimal therapeutic strategy for treating patients with hypertension and atherosclerosis: focus on olmesartan medoxomil
by: R. P. Mason
Published: (2012-06-01) -
Looking for an optimal antihypertensive combination. Focus on azilsartan medoxomil/chlorthalidone
by: M. D. Smirnova, et al.
Published: (2025-01-01) -
Host–Guest Complexation of Olmesartan Medoxomil by Heptakis(2,6-di-O-methyl)-β-cyclodextrin: Compatibility Study with Excipients
by: Dana Emilia Man, et al.
Published: (2024-12-01)